FINWIRES · TerminalLIVE
FINWIRES

Bullish to Acquire Equiniti From Siris in $4.2 Billion Deal

作者

-- Bullish (BLSH) on Tuesday agreed to acquire transfer agent Equiniti from private equity firm Siris in an all-stock deal worth about $4.2 billion as the digital asset platform aims to build infrastructure for tokenized securities.

The transaction comprises $1.85 billion of Equiniti's debt and about $2.35 billion in Bullish shares, priced at $38.48 apiece, the crypto exchange said in a statement. Bullish shares gained 1.9% in the most recent premarket activity.

The deal is expected to combine Bullish's blockchain infrastructure with Equiniti's transfer agency services to create a global transfer agent platform to support tokenized securities.

"Tokenization is a once-in-a-generation shift in how capital markets operate," Bullish Chief Executive Tom Farley said. "Broad adoption at institutional scale requires three things: end-to-end tokenization services, a single, unified ledger and a broad base of blue-chip issuer relationships, at scale."

"This combination delivers all three and I believe it uniquely positions us to lead the transition to tokenized securities," Farley added.

The transaction, which requires approval from regulators, is expected to complete in January. Following completion, Equiniti will operate under the Bullish umbrella alongside Bullish Exchange and CoinDesk.

On a pro-forma basis, the combined company is expected to generate roughly $1.3 billion in adjusted revenue and more than $500 million in earnings before interest, taxes, depreciation and amortization less capital expenditure in 2026. Bullish estimates the deal to grow revenue annually by 6% to 8% from 2027 through 2029, including 20% revenue gains from tokenization and blockchain services.

The deal "strengthens our ability to support clients as markets evolve, while maintaining the stability, service, and trust they expect from Equiniti," Equiniti CEO Dan Kramer said. Kramer will continue to be responsible for the firm's daily operations and client relationships.

Siris, which first purchased Equiniti in 2021, will receive two board seats as part of the transaction. The firm will also have a call option to acquire non-core Equiniti business lines.

相關文章

Commodities

受需求疲軟影響,Avista第一季各業務板塊能源銷售量均下滑

Avista (AVA) 週二公佈了第一季財報。受溫和天氣影響,電力和天然氣需求下降,其中居民用電量下降 10%,商業用電量下降 6%。 該公司報告稱,其營運部門 Avista Utilities 的居民用電總量為 1.15 吉瓦時,低於去年同期的 1.27 吉瓦時。 截至 3 月 31 日的第一季度,商業用電量為 768 兆瓦時,低於去年同期的 808 兆瓦時。 該公司報告稱,第一季工業用電量為 455 兆瓦時,低於去年同期的 469 兆瓦時;批發用電量為 912 兆瓦時,低於去年同期的 951 兆瓦時。 該公司報告稱,其營運部門 Avista Utilities 的住宅天然氣總銷量為 8,4907 億英熱單位(Btu),低於去年同期的 9,8,881 億英熱單位。 截至 3 月 31 日的季度,商業天然氣銷售量為 5,1161 億英熱單位,低於去年同期的 5,9619 億英熱單位。 該公司報告稱,第一季天然氣批發量為 5,4,461 億英熱單位,低於去年同期的 6,7,528 億英熱單位。 其他天然氣銷售量為 5,4461 億英熱單位,低於去年同期的 5,4019 億英熱單位。 Avista 也正在推動一項新的企業資源規劃系統,該系統計劃於 2028 年完成,預計資本支出約為 1.3 億美元,旨在提高營運效率和財務報告能力。Price: $40.81, Change: $+0.25, Percent Change: +0.62%

$AVA
Australia

加拿大皇家銀行表示,Primo Brands第一季面臨服務中斷和成本上漲的雙重壓力。

加拿大皇家銀行資本市場(RBC Capital Markets)週二在一份電子郵件報告中指出,受冬季風暴導致的長期服務中斷以及中東衝突引發的投入成本上升的影響,Primo Brands (PRMB) 預計第一季業績將面臨壓力。 該機構表示,第一季可能是全年業績最疲軟的季度,冬季風暴造成的損失或無法挽回的交付銷售額可能會進一步影響業績。 RBC指出,零售業務趨勢似乎對Primo Brands有利,掃描數據顯示銷售額成長了6%。 RBC還補充說,該公司已對其核心包裝業務以外的約15%的零售銷售進行了定價。 報告稱,Primo Brands仍然高度關注石油相關成本,包括樹脂、玻璃、鋁和柴油等,儘管該公司已為2026年進行了大量的對沖,並擁有定價和燃油附加費等應對手段。 Primo Brands預計將於週四公佈第一季財務業績。 RBC維持對Primo Brands的「跑贏大盤」評級,並維持其28美元的目標價。Price: $20.37, Change: $+0.27, Percent Change: +1.37%

$PRMB
Australia

摩根士丹利稱,BioMarin在與Amicus達成交易後,酵素產品組合擴大,進入「轉型年」。

摩根士丹利週二發布的一份報告稱,BioMarin Pharmaceutical (BMRN) 將於2026年進入“轉型年”,在收購Amicus Therapeutics (FOLD) 後,其酶製劑產品組合規模擴大,公司將優先考慮加速增長和提升市場份額。 報告指出,BioMarin在第一季財報中將2026財年營收預期上調至38.25億美元至39.25億美元,主要得益於新增療法Galafold和Pombilityi以及Opfolda的貢獻;但由於與此交易相關的整合成本和更高的利息支出,公司將非GAAP每股收益下調至4.855.505美元。 摩根士丹利表示,BioMarin正專注於擴大其酵素製劑產品組合的規模並推進商業化進程,預計其管理層將在第二季度公佈一份詳細的路線圖,涵蓋「長期營收潛力」、銷售峰值和成本協同效應。 報告指出,預計盈利將主要集中在2026年下半年,管理層認為收購Amicus的交易今年會“略微稀釋”盈利,但12個月內將“增值”,並在2027年初發揮更大作用。 報告稱,「合併後的酵素產品組合」可望支撐持續成長,並有助於抵消Voxzogo日益激烈的競爭;同時,包括Palynziq擴充和BMN-333在內的管線開發和新產品上市,並有望進一步支持長期成長。 摩根士丹利維持對BioMarin Pharmaceutical的「增持」評級,並將目標股價從120美元下調至119美元。Price: $54.26, Change: $-1.20, Percent Change: -2.16%

$BMRN$FOLD